Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more favorable properties could aid in the creation of T-BsAbs with impro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:MAbs
Autors principals: Trinklein, Nathan D., Pham, Duy, Schellenberger, Ute, Buelow, Ben, Boudreau, Andrew, Choudhry, Priya, Clarke, Starlynn C., Dang, Kevin, Harris, Katherine E., Iyer, Suhasini, Jorgensen, Brett, Pratap, Payal P., Rangaswamy, Udaya S., Ugamraj, Harshad S., Vafa, Omid, Wiita, Arun P., van Schooten, Wim, Buelow, Roland, Force Aldred, Shelley
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2019
Matèries:
Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6601548/
https://ncbi.nlm.nih.gov/pubmed/30698484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1574521
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars